June 2, 2021 07:42 AM EDTUpdated 10:59 AM

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Germany’s MorphoSys has swooped in to buy cancer drug developer Constellation $CNST in a deal that values the company at $1.7 billion. And they’re funding …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact

John Carroll

Editor & Founder

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Mor­phoSys swoops in with a $1.7B deal to buy Con­stel­la­tion, adds $2B-plus in Roy­al­ty pact

Editor & Founder

Editor

Sign up to read this article for free.

MorphoSys swoops in with a $1.7B deal to buy Constellation, adds $2B-plus in Royalty pact